Evaluation of SmartSleep Technology for Improving the Efficiency and Restorative Quality of Sleep in Healthy Adults
NCT ID: NCT03911154
Last Updated: 2022-10-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
9 participants
INTERVENTIONAL
2019-04-29
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Slow-wave Enhancement in Adults Aged 30-49
NCT04611828
Enhancing Sleep Slow Waves Using External Stimuli
NCT03323814
Acoustic Stimulation During Restricted Sleep After Sleep Deprivation
NCT05309473
Light Sleep: Screen Use and Sleep Health
NCT05342662
Smart Pillows for Enhancing Sleep Quality
NCT06594627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will use SmartSleep (Philips) technology to determine what effect the device has on daytime cognitive performance after emergent awakenings from sleep in a chronic sleep restriction paradigm. The SmartSleep technology uses two small sensors in the headband to continuously detect the brain's slow wave sleep (delta/theta frequency) in real time, and a closed-loop algorithm customizes the timing and volume of tones to optimize the sleep pattern. Thus, the device uses "quiet audio tones" (sub-awareness) to increase slow waves, which can enhance sleep quality/depth, thereby enhancing subsequent waking cognitive performance without the unwanted sedating effects of medications on cognitive functions during emergency awakenings.
Subjects will be in the laboratory for 7 days/6 nights. Night 1 will be an adaptation night with 8-hours time in bed. Nights 2-5 will consist of 5 hours time in bed, followed by night 6 of a recovery 10 hours time in bed. During nights 2-5, subjects will receive one of four stimulation modalities using the SmartSleep wearable device. Subjects will receive all four modalities in a randomized order:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Cognitive performance testing and self-report surveys will be completed on a daily basis. A total of 12 healthy astronaut-like adults will be studied. Subjects will complete the 7-day study in groups of 4.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SmartSleep Continuous Fixed Interval modality
This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.
This study arm tests the SmartSleep Continuous Fixed Interval stimulation modality during sleep relative to the SHAM condition. The Continuous Fixed Interval is the delivery of auditory tones a 1 Hz inter-tone interval stimulation.
Philips SmartSleep Technology--Continuous Fixed Interval modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--Block modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--In-Phase Adjustable modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
SmartSleep Block modality
This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.
This study arm tests the SmartSleep Block stimulation modality during sleep relative to the SHAM condition. The Block is the delivery of auditory tones for 5 seconds on versus 5 seconds off.
Philips SmartSleep Technology--Continuous Fixed Interval modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--Block modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--In-Phase Adjustable modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
SmartSleep In-Phase Adjustable modality
This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.
This study arm tests the SmartSleep In-Phase Adjustable stimulation modality during sleep relative to the SHAM condition. The In-Phase Adjustable is the constant stimulation with auditory tones delivered during each upstate of the slow wave.
Philips SmartSleep Technology--Continuous Fixed Interval modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--Block modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--In-Phase Adjustable modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
SHAM condition
This study uses within subject comparison. For each subject, the order of 3 SmartSleep modalities for each of the 4 nights of sleep restriction will be randomized. All subjects will receive all 3 stimulation modalities and a SHAM condition.
This study arm is the SHAM condition, during which participants wore the SmartSleep device, however no auditory tones were delivered.
Philips SmartSleep Technology--Continuous Fixed Interval modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--Block modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--In-Phase Adjustable modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Philips SmartSleep Technology--Continuous Fixed Interval modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--Block modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Philips SmartSleep Technology--In-Phase Adjustable modality
During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:
1. Continuous Fixed Interval
2. Block
3. In-Phase Adjustable
4. Sham: No auditory stimulation while wearing the SmartSleep headband
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Free of psychological/psychiatric conditions that preclude participation.
* BMI \< 35.
* Self-reported regular sleep schedule; able to maintain their sleep schedule during the course of the study.
* Self-reported sleep duration of 6-8.5 hrs per night (verified by 6 work days of ambulatory sleep monitoring with wrist actigraphy and daily logs).
* Ability to read/write English.
Exclusion Criteria
* Current mania or psychosis.
* Current depression as determined by the Beck Depression Inventory (Beck, 1996).
* Alcohol or drug abuse in the past year based upon history and urine toxicology screen.
* Excessive alcohol intake (≥ 21 drinks per week) or binge alcohol consumption (\> 5 drinks per day).
* Excessive caffeine consumption (\> 650mg/day combining all caffeinated drinks regularly absorbed during the day).
* Current smoker/tobacco user, or using nicotine replacement therapy. Those that have been nicotine-free for 30 days will be included.
* Acute, chronic, or debilitating medical conditions, major Axis I psychiatric illness based on history, physical exam, blood and urine chemistries, and CBC.
* Individuals who self-report a history of recurrent seizures or epilepsy or have a history of medical conditions that could increase the chance of seizures (e.g. stroke, aneurysm, brain surgery, structural brain lesion).
* Cardiovascular, neurological, gastrointestinal, or musculoskeletal problems that exclude participation.
* Major controlled or uncontrolled medical condition such as congestive heart failure, neuromuscular disease, renal failure, cancer, COPD, respiratory failure or insufficiency, or patients requiring oxygen therapy (as determined by self-report).
* Currently working night, swing, split or rotating shift.
* Current use or use of within the past month of a prescription or over-the-counter sleep medication or stimulant; use of psychoactive medication (based on self-report and review with a study clinician).
* Pregnant or currently breast feeding
* Prior history or diagnosis of any sleep disorder
* High Risk of OSA based on STOP-BANG Questionnaire ("yes" on at least 4 of 8 questions)
* High Risk of Restless Legs Syndrome (RLS) based on Cambridge-Hopkins Screening questionnaire
* High Risk of Insomnia based on Insomnia Severity Index (score of 22 or higher)
* Individuals who self-report severe contact dermatitis or allergy to silicone, nickel or silver.
* Individuals who self-report moderate hearing loss.
* Inability to achieve appropriate headband fit.
* Planned travel across more than one time zone one month prior to and/or during the anticipated period of the study with SmartSleeps device use.
* Intentional naps during the week.
30 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Aeronautics and Space Administration (NASA)
FED
Philips Healthcare
INDUSTRY
University of Wisconsin, Madison
OTHER
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NNX16AO69A/T0408
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.